| Cover | 3 Months Ended |
| Mar. 31, 2022 | |
| Cover [Abstract] | |
| Document Type | 6-K/A |
| Amendment Flag | true |
| Amendment Description | This Report on Form 6-K/A (the “Amendment”) amends the Report on Form 6-K filed on May 5, 2022 (the “Original 6-K”) containing the Company’s unaudited Consolidated Interim Financial Statements at March 31, 2022. |
| Document Period End Date | Mar. 31, 2022 |
| Document Fiscal Period Focus | Q1 |
| Document Fiscal Year Focus | 2022 |
| Current Fiscal Year End Date | --12-31 |
| Entity File Number | 001-40377 |
| Entity Registrant Name | Valneva SE |
| Entity Central Index Key | 0001836564 |
| Unaudited Interim Condensed Consolidated Statements of Income (Loss) - EUR (€) € in Thousands | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Profit or loss [abstract] | ||
| Product sales | € 16,162 | € 16,124 |
| Other revenues | 5,686 | 7,092 |
| Revenues | 21,847 | 23,215 |
| Cost of goods and services | (13,860) | (14,650) |
| Research and development expenses | (20,689) | (27,732) |
| Marketing and distribution expenses | (2,034) | (4,941) |
| General and administrative expenses | (5,770) | (10,010) |
| Other income and expenses, net | 2,084 | 2,979 |
| OPERATING LOSS | (18,422) | (31,138) |
| Finance income | 13 | 7,695 |
| Finance expenses | (7,130) | (4,607) |
| Result from investments in associates | (19) | |
| LOSS BEFORE INCOME TAX | (25,539) | (28,070) |
| Income tax income/(expense) | (502) | 368 |
| LOSS FOR THE PERIOD | € (26,041) | € (27,702) |
| Losses per share for profit/loss for the period attributable to the equity holders of the Company, expressed in € per share | ||
| - basic | € (0.24) | € (0.30) |
| - diluted | € (0.24) | € (0.30) |
| Unaudited Interim Condensed Consolidated Statement of Comprehensive Income (Loss) - EUR (€) € in Thousands | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Profit or loss [abstract] | ||
| Loss for the period | € (26,041) | € (27,702) |
| Items that may be reclassified to profit or loss | ||
| Currency translation differences | (244) | (337) |
| Items that will not be reclassified to profit or loss | ||
| Defined benefit plan actuarial gains/(losses) | ||
| Other comprehensive loss for the period, net of tax | (244) | (337) |
| TOTAL COMPREHENSIVE LOSS FOR THE PERIOD ATTRIBUTABLE TO THE OWNERS OF THE COMPANY | € (26,285) | € (28,038) |
| Unaudited Interim Condensed Consolidated Balance Sheets - EUR (€) € in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
| ASSETS | ||
| Non-current assets | € 232,690 | € 231,520 |
| Intangible assets | 31,765 | 32,700 |
| Right of use assets | 47,562 | 48,285 |
| Property, plant and equipment | 128,418 | 125,545 |
| Investments in associates | 2,124 | 2,124 |
| Deferred tax assets | 3,304 | 3,582 |
| Other non-current assets | 19,516 | 19,282 |
| Current assets | 545,021 | 585,832 |
| Inventories | 139,725 | 124,098 |
| Trade receivables | 25,061 | 44,013 |
| Other current assets | 68,972 | 71,036 |
| Cash and cash equivalents | 311,264 | 346,686 |
| Total assets | 777,711 | 817,352 |
| EQUITY | ||
| Capital and reserves attributable to the Company’s equity holders | 148,406 | 170,581 |
| Share capital | 16,170 | 15,786 |
| Share premium | 412,799 | 409,258 |
| Other reserves | 52,452 | 52,512 |
| Accumulated deficit | (306,974) | (233,549) |
| Loss for the period | (26,041) | (73,425) |
| LIABILITIES | ||
| Non-current liabilities | 266,049 | 277,791 |
| Borrowings | 48,005 | 50,726 |
| Lease liabilities | 52,663 | 53,687 |
| Contract liabilities | 4,830 | 4,741 |
| Refund liabilities | 156,229 | 158,970 |
| Provisions | 2,975 | 8,308 |
| Deferred tax liabilities | 1,280 | 1,290 |
| Other liabilities | 68 | 69 |
| Current liabilities | 363,257 | 368,979 |
| Borrowings | 11,730 | 7,107 |
| Trade payables and accruals | 66,268 | 68,119 |
| Income tax liability | 72 | 83 |
| Tax and Employee-related liabilities | 19,838 | 17,249 |
| Lease liabilities | 3,122 | 3,135 |
| Contract liabilities | 122,478 | 124,017 |
| Refund liabilities | 100,279 | 95,611 |
| Provisions | 30,554 | 48,708 |
| Other liabilities | 8,917 | 4,950 |
| Total liabilities | 629,305 | 646,771 |
| Total equity and liabilities | € 777,711 | € 817,352 |
| Unaudited Interim Condensed Consolidated Statements of Cash Flows - EUR (€) € in Thousands | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Cash flows from operating activities | ||
| Loss for the period | € (26,041) | € (27,702) |
| Adjustments for non-cash transactions | (6,922) | 6,232 |
| Changes in non-current operating assets and liabilities | (4,763) | 1,951 |
| Changes in working capital | 11,193 | 68,373 |
| Cash generated from/(used in) operations | (26,533) | 48,855 |
| Income tax paid | (318) | (1,296) |
| Net cash generated from/(used in) operating activities | (26,851) | 47,559 |
| Cash flows from investing activities | ||
| Purchases of property, plant and equipment | (9,385) | (16,333) |
| Purchases of intangible assets | (76) | (543) |
| Interest received | 13 | 19 |
| Net cash used in investing activities | (9,447) | (16,857) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of costs of equity transactions | 3,726 | 2,209 |
| Disposal of treasury shares | 154 | |
| Payment of lease liabilities | (835) | (518) |
| Interest paid | (1,909) | (3,396) |
| Net cash generated from/(used in) financing activities | 982 | (1,550) |
| Net change in cash and cash equivalents | (35,316) | 29,152 |
| Cash and cash equivalents at beginning of the period | 346,642 | 204,394 |
| Exchange gains/(losses) on cash | (107) | 2,324 |
| Restricted cash | 45 | 43 |
| Cash and cash equivalents at end of the period | € 311,264 | € 235,913 |
| Unaudited Interim Condensed Consolidated Statements of Changes in Equity € in Thousands | Issued capital [member] EUR (€) shares | Share premium [member] EUR (€) | Other reserves [member] EUR (€) | Retained earnings, excluding profit (loss) for reporting period [member] EUR (€) | Retained earnings, profit (loss) for reporting period [member] EUR (€) | EUR (€) |
| Balance at Dec. 31, 2020 | € 13,646 | € 244,984 | € 52,342 | € (169,156) | € (64,393) | € 77,422 |
| Beginning balance (in shares) at Dec. 31, 2020 | shares | 90,970,562 | |||||
| Total comprehensive loss | (337) | (27,702) | (28,038) | |||
| Income appropriation | (64,393) | 64,393 | ||||
| Share-based compensation expense: | ||||||
| - value of services | 608 | 608 | ||||
| - exercises | € 119 | 2,090 | 2,209 | |||
| Exercises, number of shares issued | shares | 793,200 | |||||
| Treasury shares | 154 | 154 | ||||
| Balance at Mar. 31, 2021 | € 13,765 | 247,074 | 52,768 | (233,549) | (27,702) | 52,355 |
| Ending balance (in shares) at Mar. 31, 2021 | shares | 91,763,762 | |||||
| Balance at Dec. 31, 2021 | € 15,786 | 409,258 | 52,512 | (233,549) | (73,425) | 170,581 |
| Beginning balance (in shares) at Dec. 31, 2021 | shares | 105,239,085 | |||||
| Total comprehensive loss | (244) | (26,041) | (26,285) | |||
| Income appropriation | (73,425) | 73,425 | ||||
| Share-based compensation expense: | ||||||
| - value of services | 185 | 185 | ||||
| - exercises | € 384 | 3,541 | 3,925 | |||
| Exercises, number of shares issued | shares | 2,563,011 | |||||
| Treasury shares | ||||||
| Balance at Mar. 31, 2022 | € 16,170 | € 412,799 | € 52,452 | € (306,974) | € (26,041) | € 148,406 |
| Ending balance (in shares) at Mar. 31, 2022 | shares | 107,802,096 |
